

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/022677-2024>

Tender

## **Provision of Community Pharmacy Respiratory Syncytial Virus (RSV) Vaccination within the East of England Region**

NHS England

F02: Contract notice

Notice identifier: 2024/S 000-022677

Procurement identifier (OCID): ocds-h6vhtk-048349

Published 22 July 2024, 1:59pm

### **Section I: Contracting authority**

#### **I.1) Name and addresses**

NHS England

7-8 Wellington Place

Leeds

LS1 4AP

#### **Contact**

Stacey Thrower

#### **Email**

[stacey.thrower@nhs.net](mailto:stacey.thrower@nhs.net)

#### **Country**

United Kingdom

#### **Region code**

UK - United Kingdom

**Internet address(es)**

Main address

<https://www.england.nhs.uk/>

Buyer's address

<https://www.england.nhs.uk/>

**I.3) Communication**

The procurement documents are available for unrestricted and full direct access, free of charge, at

<https://health-family.force.com/s/Welcome>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<https://health-family.force.com/s/Welcome>

Tenders or requests to participate must be submitted to the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

<https://health-family.force.com/s/Welcome>

**I.4) Type of the contracting authority**

Body governed by public law

**I.5) Main activity**

Health

---

## Section II: Object

### II.1) Scope of the procurement

#### II.1.1) Title

Provision of Community Pharmacy Respiratory Syncytial Virus (RSV) Vaccination within the East of England Region

Reference number

AG24517

#### II.1.2) Main CPV code

- 85100000 - Health services

#### II.1.3) Type of contract

Services

#### II.1.4) Short description

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHE England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy Respiratory Syncytial Virus (RSV) Vaccination within the East of England Region

Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:

- an adult programme (predominately to be commissioned through general practice); and
- an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).

This Procurement Process is for the Early Adoption Phase in the East of England Region where up to 50 Potential Suppliers will be selected to provide the services. The 50 Successful Suppliers will be in 2 ICBs within the East of England Region to allow the Commissioner to ensure an even geographical spread. The ICB's included in this procurement are NHS Mid and South Essex ICB and Suffolk and North East Essex ICB.

The value of the service provision resulting from this Procurement Process will be an Item

of Service (IoS) fee of £9.58 for the administration of each RSV vaccine to each eligible patient.

The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner's control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.

Services will commence in September 2024 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.

Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on 7th August 2024.

### **II.1.6) Information about lots**

This contract is divided into lots: Yes

Tenders may be submitted for one lot only

## **II.2) Description**

### **II.2.1) Title**

Lot 1 - NHS Mid and South Essex ICB

Lot No

1

### **II.2.2) Additional CPV code(s)**

- 85100000 - Health services

### **II.2.3) Place of performance**

NUTS codes

- UKH - East of England

### **II.2.4) Description of the procurement**

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHE England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy Respiratory Syncytial Virus (RSV) Vaccination within the East of England Region

Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:

- an adult programme (predominately to be commissioned through general practice); and
- an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).

This Procurement Process is for the Early Adoption Phase in the East of England Region where up to 50 Potential Suppliers will be selected to provide the services. The 50 Successful Suppliers will be in 2 ICBs within the East of England Region to allow the Commissioner to ensure an even geographical spread. The ICB's included in this procurement are NHS Mid and South Essex ICB and Suffolk and North East Essex ICB.

The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV vaccine to each eligible patient.

The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner's control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.

Services will commence in September 2024 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.

The award criteria is as stated below:

Integration, collaboration and service sustainability - 40.00%  
Improving access, reducing health inequalities and facilitating choice - 45.00%  
Quality and Innovation - 5.00%  
Social Value - 10.00%  
Value - Pass / Fail

Please see published procurement documentation for further details. All relevant information on the stages of evaluation are stated within the ITT documentation suite.

Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on 7th August 2024.

## **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

23 September 2024

End date

31 March 2029

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: No

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 2 - Suffolk and North East Essex ICB

Lot No

2

### **II.2.2) Additional CPV code(s)**

- 85100000 - Health services

### **II.2.3) Place of performance**

NUTS codes

- UKH - East of England

#### **II.2.4) Description of the procurement**

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHE England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy Respiratory Syncytial Virus (RSV) Vaccination within the East of England Region

Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:

- an adult programme (predominately to be commissioned through general practice); and
- an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).

This Procurement Process is for the Early Adoption Phase in the East of England Region where up to 50 Potential Suppliers will be selected to provide the services. The 50 Successful Suppliers will be in 2 ICBs within the East of England Region to allow the Commissioner to ensure an even geographical spread. The ICB's included in this procurement are NHS Mid and South Essex ICB and Suffolk and North East Essex ICB.

The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV vaccine to each eligible patient.

The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner's control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.

Services will commence in September 2024 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.

The award criteria is as stated below:

Integration, collaboration and service sustainability - 40.00%

Improving access, reducing health inequalities and facilitating choice - 45.00%

Quality and Innovation - 5.00%

Social Value - 10.00%  
Value - Pass / Fail

Please see published procurement documentation for further details. All relevant information on the stages of evaluation are stated within the ITT documentation suite.

Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on 7th August 2024.

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Start date

3 September 2024

End date

31 March 2029

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: No

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

---

## **Section III. Legal, economic, financial and technical information**

### **III.1) Conditions for participation**

#### **III.1.2) Economic and financial standing**

Selection criteria as stated in the procurement documents

#### **III.1.3) Technical and professional ability**

Selection criteria as stated in the procurement documents

---

## **Section IV. Procedure**

### **IV.1) Description**

#### **IV.1.1) Type of procedure**

Open procedure

#### **IV.1.8) Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: No

### **IV.2) Administrative information**

#### **IV.2.2) Time limit for receipt of tenders or requests to participate**

Date

7 August 2024

Local time

12:00pm

#### **IV.2.4) Languages in which tenders or requests to participate may be submitted**

English

#### **IV.2.6) Minimum time frame during which the tenderer must maintain the tender**

Duration in months: 6 (from the date stated for receipt of tender)

#### **IV.2.7) Conditions for opening of tenders**

Date

22 July 2024

Local time

2:00pm

---

## **Section VI. Complementary information**

### **VI.1) Information about recurrence**

This is a recurrent procurement: No

### **VI.3) Additional information**

This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.

The Contracting Authority will be using an eTendering system for this procurement exercise.

Further information and the ITT documentation can be found via the 'Live Opportunities' list on the e-tendering system at the following link:

<https://health-family-contract-search.secure.force.com/?searchtype=Projects>

You can also register your interest via this page. You can search for the opportunity by entering the following contract reference: C297044 - COMPETITIVE: RSV Community Pharmacy Pathfinder Service

Neither the publication of this notice nor the employment of any particular terminology nor any other indication shall be taken to mean that the Contracting Authority intends to hold itself bound by any of the Regulations.

The award criteria is as stated below:

Integration, collaboration and service sustainability - 40.00%  
Improving access, reducing health inequalities and facilitating choice - 45.00%  
Quality and Innovation - 5.00%  
Social Value - 10.00%  
Value - Pass / Fail

Please see published procurement documentation for further details. All relevant information on the stages of evaluation are stated within the ITT documentation suite.

### **VI.4) Procedures for review**

#### **VI.4.1) Review body**

NHS England

7-8 Wellington Place

Leeds

LS1 4AP

Country

United Kingdom

Internet address

<https://www.england.nhs.uk/>

**VI.4.2) Body responsible for mediation procedures**

NHS Arden and GEM CSU

St John's House, East Street

Leicester

LE1 6NB

Country

United Kingdom

Internet address

<https://www.ardengemcsu.nhs.uk/>

**VI.4.4) Service from which information about the review procedure may be obtained**

NHS Arden and GEM CSU

St John's House, East Street

Leicester

LE1 6NB

Country

United Kingdom

Internet address

<https://www.ardengemcsu.nhs.uk/>